PER — Percheron Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$6.09m
- AU$2.07m
- AU$0.15m
Brief: Antisense Therapeutics Seeks Trading Halt
Brief: Antisense Therapeutics Gets Mhra Approval To Conduct Phase IIb Trial In UK For Atl1102
Brief: Antisense Therapeutics Announces Appointment Of James Garner As CEO
Aussie Antisense Therapeutics up on trial nod for muscular dystrophy drug
Brief: Antisense Therapeutics Says Atl1102 Phase IIB DMD Trial Bulgarian Approval Received
Brief: Antisense Therapeutics Posts HY Net Loss For Period Attributable A$5.3 Mln
Brief: Antisense Therapeutics Submits Clinical Trial Application For Atl1102 Phase Iib Dmd Trial In Europe
Brief: Antisense Therapeutics Says Mark Diamond Advised Of Retirement As CEO
Brief: Antisense Therapeutics Says FY Net Loss Attributable A$5.8 Million
Brief: Antisense Therapeutics Seeks Trading Halt-Anp.Ax
Australia's Antisense Therapeutics rises on positive trial data for drug
Australia Stock Exchange release from ANTISENSE THERAP : Plasma protein data supports bone density improvement in DMD
Australia Stock Exchange release from ANTISENSE THERAP : Poster Presentation at 2022 MDA Conference
Brief: Antisense Therapeutics Announces Long COVID-19 Strategic Collaboration With U.S. Experts
Australia Stock Exchange release from ANTISENSE THERAP : Long COVID-19 strategic collaboration with US Experts
Australia Stock Exchange release from ANTISENSE THERAP : PRE_NR Ends: 13:05:31
Australia Stock Exchange release from ANTISENSE THERAP : Half Yearly Report and Accounts
Australia Stock Exchange release from ANTISENSE THERAP : PRE_NR Ends: 17:47:10
Australia Stock Exchange release from ANTISENSE THERAP : ANP to present at XIX International Conference on DMD